NCT01415284

Brief Summary

The purpose of this trial is to determine the effective volume of hydroxyethylstarch 130/0.4 which would prevent the occurence of maternal hypotension in 50% of healthy pregnant women undergoing a cesarean section under spinal anesthesia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Oct 2011

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 10, 2011

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 11, 2011

Completed
2 months until next milestone

Study Start

First participant enrolled

October 1, 2011

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

February 15, 2013

Status Verified

February 1, 2013

Enrollment Period

1.7 years

First QC Date

August 10, 2011

Last Update Submit

February 12, 2013

Conditions

Keywords

Obstetric anesthesiaSpinal anesthesiaHypotensionFluid therapyCesarean sectionphenylephrinecardiac output

Outcome Measures

Primary Outcomes (1)

  • Volume of HES which will prevent hypotension if 50 % of the subjects.

    4 months

Secondary Outcomes (6)

  • Incidence of hypotension episodes

    1 hour

  • Incidence of hypertensive episodes

    1 hour

  • cardiac output

    1 hour

  • Apgar score

    10 minutes

  • umbilical artery pH

    2 hours

  • +1 more secondary outcomes

Study Arms (1)

Hydroxyethylstarch 130/0.4

EXPERIMENTAL
Drug: Hydroxyethylstarch 130/0.4

Interventions

first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.

Also known as: Voluven
Hydroxyethylstarch 130/0.4

Eligibility Criteria

Sexfemale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy pregnant women (ASA I or II)
  • Normal pregnancy
  • Term gestation (37 weeks and above)
  • Elective cesarean section
  • Spinal anesthesia

You may not qualify if:

  • Cardiopathies
  • Hypertensive disease/ pre-eclampsia / eclampsia
  • Any contraindication to neuraxial anesthesia
  • Patient refusal
  • Body mass index \> 30 at first antenatal visit and \> 32 at cesarean section
  • Twin pregnancy
  • Known allergies to HES
  • Emergency cesarean section

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Maisonneuve-Rosemont Hospital

Montreal, Quebec, H1T 2M4, Canada

RECRUITING

MeSH Terms

Conditions

Hypotension

Interventions

HES 130-0.4

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

  • Christian Loubert, MD, FRCPC

    Maisonneuve-Rosemont Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Christian Loubert, MD, FRCPC

CONTACT

Louis-Philippe Fortier, MD, FRCPC

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr

Study Record Dates

First Submitted

August 10, 2011

First Posted

August 11, 2011

Study Start

October 1, 2011

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

February 15, 2013

Record last verified: 2013-02

Locations